{"id":1113,"date":"2025-05-29T09:57:01","date_gmt":"2025-05-29T09:57:01","guid":{"rendered":"https:\/\/www.udenyca.com\/cms\/?page_id=1113"},"modified":"2026-01-08T03:40:41","modified_gmt":"2026-01-08T03:40:41","slug":"why-udenyca","status":"publish","type":"page","link":"https:\/\/www.udenyca.com\/cms\/hcp-home\/why-udenyca\/","title":{"rendered":"Why Udenyca"},"content":{"rendered":"","protected":false},"excerpt":{"rendered":"","protected":false},"author":2,"featured_media":0,"parent":856,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_acf_changed":false,"footnotes":""},"class_list":["post-1113","page","type-page","status-publish","hentry"],"acf":{"banner_image":1115,"heading":" UDENYCA<sup>&reg;<\/sup> is designed to <span className=\"yellowtxt\">support<\/span> your patient\u2019s CANCER TREATMENT journey","section_2_title_hcp":"The impact of febrile neutropenia and guidelines for treatment","featured_lists":" <p> Febrile neutropenia (FN) is a common and potentially <span class=\"no-wrap\">life-threatening<\/span> complication of chemotherapy<sup>1-3<\/sup> <\/p>\r\n<ul > <li >For patients with cancer who visit the emergency department for FN,<span> nearly all visits end in hospitalization<sup>4<\/sup><\/span><\/li>\r\n<li > FN can cause treatment delays and <span> dose reductions, leading to negative outcomes<sup>1<\/sup><\/span> <\/li>\r\n<\/ul>","gride_box_1":"AVERAGE LENGTH OF HOSPITAL STAY DUE TO FN:","gride_box_1_icon":1116,"gride_box_1_short_descript_secton_1":"<h3 class=\"firasansgreen36 mobile\">5.7-9.6 days<\/h3> <p class=\"darkgreyfirasans18withbg mobile\">FOR ADULTS<sup>5,6<\/sup><\/p>","gride_box_1_short_descript_secton_2":" <h3 class=\"firasansgreen36 mobile\">6.2-6.8 days<\/h3><p class=\"darkgreyfirasans18withbg mobile\">FOR ELDERLY PATIENTS<sup>7<\/sup><\/p>","gride_box_2_title":"Mortality rate in adults with cancer hospitalized for neutropenia\/FN:","gride_box_2_short_descript_secton_1":"<h3 class=\"firasansgreen64 mobile\">2.6%-7.0%<\/h3>\r\n<p class=\"darkgreyfirasans18\">(solid tumors)<sup>4,5<\/sup><\/p>","gride_box_2_short_descript_secton_2":"<h3 class=\"firasansgreen64 mobile\">7.4%<\/h3>\r\n<p class=\"darkgreyfirasans18\">(hematologic malignancies)<sup>4<\/sup><\/p>","section_3_title":"Disease-related factors that increase the likelihood of hospitalization for neutropenia\/FN include:","section_3_list_items":" <ul role=\"list\" class=\"disease-list mobile\">\r\n<li class=\"disease-list-item mobile\">Older age<\/li>\r\n<li class=\"disease-list-item mobile\">Presence of comorbidities<\/li>\r\n<\/ul>\r\n<ul id=\"w-node-ac5fa9f4-4c82-53ca-8ee1-605ffcd78bda-dc66f1c2\" role=\"list\" className=\"disease-list mobile second cellphone\">\r\n<li class=\"disease-list-item mobile\">Advanced-stage disease<\/li>\r\n<li class=\"disease-list-item mobile\">First-cycle chemotherapy with average relative dose intensity \u226585%<sup>3,4<\/sup><\/li>\r\n<\/ul>","section_fn_title":"FN can result in a high cost to the healthcare system ","section_fn_image_1":1117,"section_fn_image_mob":1118,"administration_options_title":"THREE ADMINISTRATION OPTIONS","administration_options_icon":1119,"administration_options_des":"Multiple administration options allow you to prescribe based on the needs of your patients.","administration_options_url":"https:\/\/www.udenyca.com\/hcp\/administration-options\/","administration_options_button_text":"Explore administration options","established_outcomes_title":"ESTABLISHED OUTCOMES","established_outcomes_desc":"UDENYCA<sup>\u00ae<\/sup> was demonstrated to be highly similar to Neulasta<sup>\u00ae<\/sup>, with no clinically meaningful differences.<sup>10,11<\/sup>","established_outcomes_icon":1120,"established_outcomes_button_text":"Review clinical data","established_outcomes_button_url":"https:\/\/www.udenyca.com\/hcp\/established-outcomes\/","section_ncc_title":"<h3>NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) recommendation for <span class=\"no-wrap\">G-CSF<\/span> use during chemotherapy<sup>8<\/sup><\/h3>                             <p>G-CSF (e.g., pegfilgrastim) primary prophylaxis may support optimal dose intensity and clinical outcomes in certain patients undergoing myelosuppressive chemotherapy.<sup>9<\/sup><\/p>                         ","section_ncc_sub_hedaing":"<p><strong> When FN risk is &gt;20%, <span class=\"no-wrap\">G-CSF<\/span> prophylaxis<sup>*9<\/sup>:  <\/strong><\/p>","section_ncc__image_1":1121,"section_ncc__description":"<h2>Reduced the risk of FN<sup>9<\/sup><\/h2>\r\n<p>(RR: 0.54; 95% CI, 0.43-0.67)<\/p>","section_ncc_image_2":1122,"section_ncc_sub_headings_and_description":"<h3>Significantly improved the relative dose intensity (RDI) of chemotherapy with an average difference in RDI of 8.4%<sup>9<\/sup><\/h3>\r\n<p ><span class=\"no-wrap\">(G-CSF-treated<\/span> patients vs <span class=\"no-wrap\">non-G-CSF-treated<\/span> patients)<\/p>","important_considerations":" <p><strong>\r\n    <span class=\"no-wrap\"> G-CSF<\/span> was shown to increase RDI and is associated with survival benefit<sup>\u20209<\/sup>\r\n                                <\/strong><\/p>","important_considerations_description":" <p class=\"impp1\">Important considerations<\/p>\r\n \r\n<p>*Results from a systematic review of 17 randomized trials, which included 3493 patients with solid tumors and lymphoma. <span class=\"no-wrap\">G-CSF<\/span> included filgrastim and pegfilgrastim.<br \/><\/p>\r\n<p class=\"ncnn-body mobile cellphone\">\u2020Survival benefit not included in UDENYCA<sup>\u00ae<\/sup> prescribing information.<\/p> \r\n <p class=\"ncnn-body-smaller mobile cellphone\">CI = confidence interval; <span class=\"no-wrap\">G-CSF<\/span> = granulocyte colony stimulating factor; RR = relative risk.   <\/p>","banner_image_url":"https:\/\/www.udenyca.com\/cms\/wp-content\/uploads\/2025\/05\/why-udenyca-hero-1.svg","gride_box_1_icon_url":"https:\/\/www.udenyca.com\/cms\/wp-content\/uploads\/2025\/05\/Hospital-Stay_Icon_Green-2.0c9f1dda.svg","section_fn_image_1_url":"https:\/\/www.udenyca.com\/cms\/wp-content\/uploads\/2025\/05\/fn-desk.624a6a6f.svg","section_fn_image_mob_url":"https:\/\/www.udenyca.com\/cms\/wp-content\/uploads\/2025\/05\/fn-mobile.svg","administration_options_icon_url":"https:\/\/www.udenyca.com\/cms\/wp-content\/uploads\/2025\/05\/sir-Group.8722e282-1.svg","established_outcomes_icon_url":"https:\/\/www.udenyca.com\/cms\/wp-content\/uploads\/2025\/05\/banner_Checkmark.3bb07e3f.svg","section_ncc__image_1_url":"https:\/\/www.udenyca.com\/cms\/wp-content\/uploads\/2025\/05\/ReducedRisk1.990e36c1.svg","section_ncc_image_2_url":"https:\/\/www.udenyca.com\/cms\/wp-content\/uploads\/2025\/05\/ReducedRisk2.d15dbb2e.svg"},"banners":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v24.2 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Why UDENYCA\u00ae: Effective Febrile Neutropenia Prophylaxis<\/title>\n<meta name=\"description\" content=\"Discover how UDENYCA\u00ae (pegfilgrastim-cbqv) supports optimal chemotherapy dosing by reducing febrile neutropenia risk. Explore its clinical benefits, administration options, and patient support resources\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.udenyca.com\/cms\/hcp-home\/why-udenyca\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Why UDENYCA\u00ae: Effective Febrile Neutropenia Prophylaxis\" \/>\n<meta property=\"og:description\" content=\"Discover how UDENYCA\u00ae (pegfilgrastim-cbqv) supports optimal chemotherapy dosing by reducing febrile neutropenia risk. Explore its clinical benefits, administration options, and patient support resources\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.udenyca.com\/cms\/hcp-home\/why-udenyca\/\" \/>\n<meta property=\"og:site_name\" content=\"Udenyca\" \/>\n<meta property=\"article:modified_time\" content=\"2026-01-08T03:40:41+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\n\t    \"@context\": \"https:\/\/schema.org\",\n\t    \"@graph\": [\n\t        {\n\t            \"@type\": \"WebPage\",\n\t            \"@id\": \"https:\/\/www.udenyca.com\/hcp\/why-udenyca\/\",\n\t            \"url\": \"https:\/\/www.udenyca.com\/hcp\/why-udenyca\/\",\n\t            \"name\": \"Why UDENYCA\u00ae: Effective Febrile Neutropenia Prophylaxis\",\n\t            \"isPartOf\": {\n\t                \"@id\": \"https:\/\/www.udenyca.com\/#website\"\n\t            },\n\t            \"datePublished\": \"2025-05-29T09:57:01+00:00\",\n\t            \"dateModified\": \"2026-01-08T03:40:41+00:00\",\n\t            \"description\": \"Discover how UDENYCA\u00ae (pegfilgrastim-cbqv) supports optimal chemotherapy dosing by reducing febrile neutropenia risk. Explore its clinical benefits, administration options, and patient support resources\",\n\t            \"breadcrumb\": {\n\t                \"@id\": \"https:\/\/www.udenyca.com\/hcp\/why-udenyca\/#breadcrumb\"\n\t            },\n\t            \"inLanguage\": \"en-US\",\n\t            \"potentialAction\": [\n\t                {\n\t                    \"@type\": \"ReadAction\",\n\t                    \"target\": [\n\t                        \"https:\/\/www.udenyca.com\/hcp\/why-udenyca\/\"\n\t                    ]\n\t                }\n\t            ]\n\t        },\n\t        {\n\t            \"@type\": \"WebSite\",\n\t            \"@id\": \"https:\/\/www.udenyca.com\/#website\",\n\t            \"url\": \"https:\/\/www.udenyca.com\/\",\n\t            \"name\": \"Udenyca\",\n\t            \"description\": \"\",\n\t            \"potentialAction\": [\n\t                {\n\t                    \"@type\": \"SearchAction\",\n\t                    \"target\": {\n\t                        \"@type\": \"EntryPoint\",\n\t                        \"urlTemplate\": \"https:\/\/www.udenyca.com\/?s={search_term_string}\"\n\t                    },\n\t                    \"query-input\": {\n\t                        \"@type\": \"PropertyValueSpecification\",\n\t                        \"valueRequired\": true,\n\t                        \"valueName\": \"search_term_string\"\n\t                    }\n\t                }\n\t            ],\n\t            \"inLanguage\": \"en-US\"\n\t        },\n\t        {\n\t            \"@type\": \"Person\",\n\t            \"@id\": \"https:\/\/www.udenyca.com\/#\/schema\/person\/a844a346ec614e5a877ab0a0211f0603\",\n\t            \"name\": \"asentechssg\",\n\t            \"image\": {\n\t                \"@type\": \"ImageObject\",\n\t                \"inLanguage\": \"en-US\",\n\t                \"@id\": \"https:\/\/www.udenyca.com\/#\/schema\/person\/image\/\",\n\t                \"url\": \"https:\/\/secure.gravatar.com\/avatar\/8bd4f6eac2ebdc91ffb98cb689eb1365d18f01c01ef79198311d807848eb420d?s=96&d=mm&r=g\",\n\t                \"contentUrl\": \"https:\/\/secure.gravatar.com\/avatar\/8bd4f6eac2ebdc91ffb98cb689eb1365d18f01c01ef79198311d807848eb420d?s=96&d=mm&r=g\",\n\t                \"caption\": \"asentechssg\"\n\t            },\n\t            \"url\": \"https:\/\/www.udenyca.com\/author\/asentechssg\/\"\n\t        }\n\t    ]\n\t}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Why UDENYCA\u00ae: Effective Febrile Neutropenia Prophylaxis","description":"Discover how UDENYCA\u00ae (pegfilgrastim-cbqv) supports optimal chemotherapy dosing by reducing febrile neutropenia risk. Explore its clinical benefits, administration options, and patient support resources","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.udenyca.com\/cms\/hcp-home\/why-udenyca\/","og_locale":"en_US","og_type":"article","og_title":"Why UDENYCA\u00ae: Effective Febrile Neutropenia Prophylaxis","og_description":"Discover how UDENYCA\u00ae (pegfilgrastim-cbqv) supports optimal chemotherapy dosing by reducing febrile neutropenia risk. Explore its clinical benefits, administration options, and patient support resources","og_url":"https:\/\/www.udenyca.com\/cms\/hcp-home\/why-udenyca\/","og_site_name":"Udenyca","article_modified_time":"2026-01-08T03:40:41+00:00","twitter_card":"summary_large_image","schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.udenyca.com\/hcp\/why-udenyca\/","url":"https:\/\/www.udenyca.com\/hcp\/why-udenyca\/","name":"Why UDENYCA\u00ae: Effective Febrile Neutropenia Prophylaxis","isPartOf":{"@id":"https:\/\/www.udenyca.com\/#website"},"datePublished":"2025-05-29T09:57:01+00:00","dateModified":"2026-01-08T03:40:41+00:00","description":"Discover how UDENYCA\u00ae (pegfilgrastim-cbqv) supports optimal chemotherapy dosing by reducing febrile neutropenia risk. Explore its clinical benefits, administration options, and patient support resources","breadcrumb":{"@id":"https:\/\/www.udenyca.com\/hcp\/why-udenyca\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.udenyca.com\/hcp\/why-udenyca\/"]}]},{"@type":"WebSite","@id":"https:\/\/www.udenyca.com\/#website","url":"https:\/\/www.udenyca.com\/","name":"Udenyca","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.udenyca.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.udenyca.com\/#\/schema\/person\/a844a346ec614e5a877ab0a0211f0603","name":"asentechssg","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.udenyca.com\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/8bd4f6eac2ebdc91ffb98cb689eb1365d18f01c01ef79198311d807848eb420d?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/8bd4f6eac2ebdc91ffb98cb689eb1365d18f01c01ef79198311d807848eb420d?s=96&d=mm&r=g","caption":"asentechssg"},"url":"https:\/\/www.udenyca.com\/author\/asentechssg\/"}]}},"_links":{"self":[{"href":"https:\/\/www.udenyca.com\/cms\/wp-json\/wp\/v2\/pages\/1113","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.udenyca.com\/cms\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.udenyca.com\/cms\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.udenyca.com\/cms\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.udenyca.com\/cms\/wp-json\/wp\/v2\/comments?post=1113"}],"version-history":[{"count":24,"href":"https:\/\/www.udenyca.com\/cms\/wp-json\/wp\/v2\/pages\/1113\/revisions"}],"predecessor-version":[{"id":1450,"href":"https:\/\/www.udenyca.com\/cms\/wp-json\/wp\/v2\/pages\/1113\/revisions\/1450"}],"up":[{"embeddable":true,"href":"https:\/\/www.udenyca.com\/cms\/wp-json\/wp\/v2\/pages\/856"}],"wp:attachment":[{"href":"https:\/\/www.udenyca.com\/cms\/wp-json\/wp\/v2\/media?parent=1113"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}